Meds & supplements › Enasidenib
Medicine
IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
WARNING: DIFFERENTIATION SYNDROME Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated.
IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. 1.1 Acute Myeloid Leukemia IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
IDHIFA may cause serious side effects, including: Differentiation Syndrome. Differentiation syndrome is a condition that affects your blood cells which may be life-threatening or lead to death if not treated. Differentiation syndrome has happened within 1 day and up to 5 months after starting IDHIFA. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome during treatment with IDHIFA: o fever o cough o shortness of breath o swelling of arms and legs o swelling around neck, groin, or underarm area o fast weight gain (greater than 10 pounds within a week) o bone pain If you develop any of these symptoms of differentiation syndrome, your healthcare provider may start you on a medicine taken by mouth or given through a vein (intravenous) called corticosteroids and may monitor you in the hospital.
What is IDHIFA? IDHIFA is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if IDHIFA is safe and effective in children. Before taking IDHIFA, tell your healthcare provider about all of your medical conditions, including if you: Are pregnant or plan to become pregnant.
IDHIFA can cause harm to your unborn baby if taken during pregnancy. o If you are able to become pregnant, your healthcare provider will do a pregnancy test before you start taking IDHIFA. o Females who are able to become pregnant should use effective birth control (contraception) during treatment with IDHIFA and for 2 months after your last dose of IDHIFA.
o IDHIFA may affect how hormonal contraceptives work and may cause them to not work as well. You should use an effective non-hormonal contraceptive method during treatment with IDHIFA and for 2 months after your last dose of IDHIFA if you use hormonal contraceptives. o Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with IDHIFA.
o Males who have female partners that are able to become pregnant should use effective birth control during treatment with IDHIFA and for 2 months after your last dose of IDHIFA. o Talk to your healthcare provider about birth control methods that may be right for you during treatment with IDHIFA. o IDHIFA may cause fertility problems in females and males, which may affect your ability to have children.
Talk to your healthcare provider if you have concerns about fertility. Are breastfeeding or plan to breastfeed. It is not known if IDHIFA passes into your breast milk. You should not breastfeed during your treatment with IDHIFA and for 2 months after your last dose of IDHIFA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Take IDHIFA exactly as your healthcare provider tells you to. Take IDHIFA 1 time a day at the same time each day. Swallow IDHIFA tablets whole. Do not chew, split, or crush IDHIFA tablets. Swallow IDHIFA with 8 ounces (one cup) of water. IDHIFA can be taken with or without food. If you miss a dose of IDHIFA or vomit after taking a dose of IDHIFA, take the dose of IDHIFA as soon as possible on the same day.
Then take your next dose the next day at your regularly scheduled time.
IDHIFA may cause serious side effects, including: The most common side effects of IDHIFA include: nausea vomiting diarrhea jaundice decreased appetite Tell your healthcare provider if you have any changes to the color of your skin or the whites of your eyes. Your healthcare provider will monitor you for side effects during treatment and may tell you to stop taking IDHIFA if you develop certain side effects.
These are not all the possible side effects of IDHIFA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA-1088.
Do not take 2 doses at the same time to make up for the missed dose. Your healthcare provider should do blood tests to check your blood counts before you start IDHIFA treatment and at a minimum of every 2 weeks for at least the first 3 months during treatment to check for side effects.
Store IDHIFA at room temperature between 68°F to 77°F (20°C to 25°C). Keep IDHIFA in the original container. Keep the container tightly closed with desiccant canister inside to protect the tablets from moisture. Keep IDHIFA and all medicines out of the reach of children.
sofidex [Internet]. Daloreum; c2026. Enasidenib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/enasidenib
sofidex. (2026, August 2). Enasidenib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/enasidenib
Enasidenib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/enasidenib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.